Drug Addiction : From Basic Research to Therapy /
| Autor Corporativo: | |
|---|---|
| Otros Autores: | , |
| Formato: | eBook |
| Lenguaje: | English |
| Publicado: |
New York, NY :
Springer New York : Imprint: Springer,
2008.
|
| Edición: | 1st ed. 2008. |
| Materias: |
Tabla de Contenidos:
- General Topics
- DARPP-32 Mediates the Actions of Multiple Drugs of Abuse
- Drug Discovery From Natural Sources
- Computational Methods in Drug Design: Modeling G Protein-Coupled Receptor Monomers, Dimers, and Oligomers
- Symbiotic Relationship of Pharmacogenetics and Drugs of Abuse
- Monoclonal Antibody Form and Function: Manufacturing the Right Antibodies for Treating Drug Abuse
- Cocaine- and Amphetamine-Regulated Transcript Peptides Play a Role in Drug Abuse and Are Potential Therapeutic Targets
- RNAi-Directed Inhibition of DC-SIGN by Dendritic Cells: Prospects for HIV-1 Therapy
- Viewing Chemokines as a Third Major System of Communication in the Brain
- Targeting the PDZ Domains of Molecular Scaffolds of Transmembrane Ion Channels
- Neuronal Nicotinic Acetylcholine Receptor Expression and Function on Nonneuronal Cells
- Transporters & Stimulants & Hallucinogens
- Role of Monoamine Transporters in Mediating Psychostimulant Effects
- Development of the Dopamine Transporter Selective RTI-336 as a Pharmacotherapy for Cocaine Abuse
- Serotonin Transporters: Implications for Antidepressant Drug Development
- Recent Advances for the Treatment of Cocaine Abuse: Central Nervous System Immunopharmacotherapy
- ? Opioids as Potential Treatments for Stimulant Dependence
- Regulation of Monoamine Transporters: Influence of Psychostimulants and Therapeutic Antidepressants
- Hallucinogen Actions on 5-HT Receptors Reveal Distinct Mechanisms of Activation and Signaling by G Protein-Coupled Receptors
- Recognition of Psychostimulants, Antidepressants, and Other Inhibitors of Synaptic Neurotransmitter Uptake by the Plasma Membrane Monoamine Transporters
- Dual Dopamine/Serotonin Releasers as Potential Medications for Stimulant and Alcohol Addictions
- Receptors of Mammalian Trace Amines
- Drug Design: Nicotine, Opioids and Related Ligands
- The Role of Crystallography in Drug Design
- Opioid Peptide-Derived Analgesics
- Opioid Ligands with Mixed ?/? Opioid Receptor Interactions: An Emerging Approach to Novel Analgesics
- Small-Molecule Agonists and Antagonists of the Opioid Receptor-Like Receptor (ORL1, NOP): Ligand-Based Analysis of Structural Factors Influencing Intrinsic Activity at NOP
- Kappa Opioid Antagonists: Past Successes and Future Prospects
- In Vitro and Direct In Vivo Testing of Mixture-Based Combinatorial Libraries for the Identification of Highly Active and Specific Opiate Ligands
- Current Status of Immunologic Approaches to Treating Tobacco Dependence: Vaccines and Nicotine-Specific Antibodies
- New Paradigms and Tools in Drug Design for Pain and Addiction
- Opioids: General
- Neuropeptide-Processing Enzymes: Applications for Drug Discovery
- CNS Drug Delivery: Opioid Peptides and the Blood-Brain Barrier
- Cell-Permeable, Mitochondrial-Targeted, Peptide Antioxidants
- Targeting Opioid Receptor Heterodimers: Strategies for Screening and Drug Development
- Homology Modeling of Opioid Receptor-Ligand Complexes Using Experimental Constraints
- Molecular Recognition of Opioid Receptor Ligands
- Role of Morphine’s Metabolites in Analgesia: Concepts and Controversies
- Mu Opioid Receptor Regulation and Opiate Responsiveness
- Agmatine: Biological Role and Therapeutic Potentials in Morphine Analgesia and Dependence
- Cannabinoid
- The Therapeutic Potential of Drugs that Target Cannabinoid Receptors or Modulate the Tissue Levels or Actions of Endocannabinoids
- Further Advances in the Synthesis of Endocannabinoid-Related Ligands
- Ajulemic Acid (IP-751): Synthesis, Proof of Principle, Toxicity Studies, and Clinical Trials
- Conformational Characteristics of the Interaction of SR141716A with the CB1 Cannabinoid Receptor as Determined Through the Use of Conformationally Constrained Analogs
- Activation of G-Proteins in Brain by Endogenous and Exogenous Cannabinoids
- 2-Arachidonoylglycerol (2-AG) Membrane Transport: History and Outlook
- Endocannabinoid Mechanisms of Pain Modulation.